Goodwill and Intangible Assets

6 Months Ended

Mar. 29, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

(13) Goodwill and Intangible Assets

Goodwill

A rollforward of goodwill activity by reportable segment from September 28, 2013 to March 29, 2014 is as follows:


	Diagnostics			Breast Health			GYN Surgical			Skeletal Health		Total
Balance at September 28, 2013	$	1,153,554		$	636,365		$	1,016,456		$	8,153	$	2,814,528
Disposition of a portion of a reporting unit		(221	)		—			—			—		(221	)
Tax adjustments		(323	)		—			—			—		(323	)
Foreign currency and other		(571	)		(3,292	)		(316	)		9		(4,170	)

Balance at March 29, 2014	$	1,152,439		$	633,073		$	1,016,140		$	8,162	$	2,809,814

Intangible Assets

Intangible assets consisted of the following:


Description	As of March 29, 2014				As of September 28, 2013
Description	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Developed technology	$	3,969,132	$	1,237,076	$	4,008,947	$	1,094,435
In-process research and development		23,000		—		24,000		—
Customer relationships and contracts		1,101,860		340,541		1,101,870		296,481
Trade names		236,846		92,183		238,103		81,844
Patents		13,452		8,762		13,026		8,495
Business licenses		2,607		738		2,647		616
Non-competition agreements		—		—		296		296

	$	5,346,897	$	1,679,300	$	5,388,889	$	1,482,167

The Company recorded impairment charges of $26.6 million and $0.5 million to developed technology and trade names, respectively, in the second quarter of fiscal 2014. In addition, the Company periodically re-evaluates the lives of its definite-lived intangible assets, and in the second quarter of fiscal 2014 shortened the life of certain corporate trade names, which will be phased out.

The estimated remaining amortization expense as of March 29, 2014 for each of the five succeeding fiscal years is as follows:


Remainder of Fiscal 2014	$	229,551
Fiscal 2015	$	403,348
Fiscal 2016	$	374,672
Fiscal 2017	$	365,541
Fiscal 2018	$	355,044

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details